Schering-Plough and Novartis: Newcomers to the Combination Market
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 37 (Table of Contents)
Published: 3 Jun-2003
DOI: 10.3833/pdr.v2003.i37.892 ISSN: 1756-7874
Section: General
Abstract
Schering-Plough and Novartis entered into an agreement to co-develop Novartis’ long-acting beta-agonist, Foradil® (formoterol) with Schering-Plough’s inhaled corticosteroid, Asmanex® (mometasone) for treating asthma and chronic obstructive pulmonary disease (COPD)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
Last Issue PDF
RSS